Susan E. Barrowcliffe, General Manager, Europe at Aimmune Therapeutics, Inc. (AIMT), sold 500 shares at $22.00 ($11K) on 2017-07-27, disclosed to the SEC on 2017-07-31.
Scheduled sale ($11k) by General Manager, Europe under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AIMT | SELL | 2017-09-27 | $500K | — | Filing → |
| AIMT | SELL | 2017-09-07 | $405K | — | Filing → |
| AIMT | SELL | 2017-07-25 | $134K | — | Filing → |